Allogenic human umbilical cord derived mesenchymal stem cell ( Hamilton Biotechnology)

人脐带间充质干细胞（汉密顿生物）

Report date: 2025/06/19 20:00:08

Base Information

Drug NameAllogenic human umbilical cord derived mesenchymal stem cell ( Hamilton Biotechnology)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Source of cells > Umbilical cord-derivedCell and gene therapy > Cell therapy > Stem cell therapy > Mesenchymal stem cells therapyCell and gene therapy > Cell therapy > Donor > Allogeneic
Mechanisms of ActionStem cell replacements
TargetsNot applicable
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Primary Ovarian InsufficiencyDiabetic Nephropathies +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesWuhan Hamilton Biotechnology Co LtdGuangzhou Hamilton Biotechnology Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesGuangzhou Hamilton Biotechnology Co LtdWuhan Hamilton Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)Primary Ovarian InsufficiencyDiabetic Nephropathies +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A